---
title: Chinese GLP-1 / Ozempic Alternatives
type: technology
url: "https://www.envisioning.com/research/helix/china__chinese-glp-1-ozempic-alternatives"
hub: helix
summary: Semaglutide (Ozempic/Wegovy) loses patent protection in China on March 20, 2026 — years before the US — with multiple Chinese firms racing to launch cheaper alternatives
---

# Chinese GLP-1 / Ozempic Alternatives

Semaglutide (Ozempic/Wegovy) loses patent protection in China on March 20, 2026 — years before the US — with multiple Chinese firms racing to launch cheaper alternatives
- Technology Readiness Level: 7/9
- Impact: 3/5
- Investment: 5/5
The GLP-1 weight-loss drug market is projected to reach $150B globally by 2030. China's early patent expiration creates a window for domestic manufacturers to produce biosimilar and improved versions of semaglutide before Western generics hit the market.

Innovent Biologics (partnered with Eli Lilly) is developing mazdutide, a dual GLP-1/glucagon agonist that showed superior weight-loss results in Phase III trials published May 2025. Multiple other Chinese firms are developing their own GLP-1 variants. Biotech out-licensing deal value from China jumped from $35B (2023) to $46B (2024).

The tradeoff: China's pharmaceutical regulatory system is faster but less transparent than the FDA. Western markets may be slow to accept Chinese-manufactured biologics. But for the 1.4 billion people in China — and billions more in the Global South — affordable GLP-1 drugs could transform obesity treatment.

---
Source: Envisioning — Technology Research Institute (https://www.envisioning.com/research/helix/china__chinese-glp-1-ozempic-alternatives)